by Damon Race | Apr 16, 2024 | In the News
Damon R. Race, President & CEO RALEIGH, N.C., April 16, 2024 /PRNewswire/ — GeneVentiv Therapeutics, developer of GENV-HEM (AAV8.FVa) for all hemophilias, announced today it has been awarded a Direct to Phase II Small Business Innovation Research (SBIR)...
by Damon Race | Jan 30, 2024 | Press
January 30, 2024 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend the BIO CEO & Investor Conference, which will be held in New York, NY from...
by Damon Race | Nov 30, 2023 | Press
November 30, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend the Biotech Showcase and BIO Partnering meetings during the J.P. Morgan...
by Damon Race | Oct 2, 2023 | Press
October 2, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO Investor Forum, which will be held in San Francisco, CA from October 17-18,...
by Damon Race | May 3, 2023 | Press
May 3, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO International 2023, which will be held in Boston, MA from June 5-8, 2023. ...
Recent Comments